missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Tocris Bioscience™ Carfilzomib

Description
Carfilzomib is a potent irreversible proteasome inhibitor. Preferentially inhibits the chymotrypsin-like β5 subunit of the constitutive 20S proteasome (IC50 = 5.2 nM) and the β5i subunit of the immunoproteasome 20Si (LMP7; IC50 = 14 nM) in vitro with minimal cross-reactivity to other proteases. Exhibits little or no effect on PGPH and T-L activities. Activates prosurvival autophagy and induces cell apoptosis. Acts synergistically with dexamethasone (Cat. No. 1126). Suppresses tumor growth in an in vivo xenograft model. Decreases bone resorption and enhances bone formation in non-tumor bearing mice.
Specifications
Specifications
| Nombre del producto químico o material | (αS)-α-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1 S)-3-methyl-1-[[(2 R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide |
| CAS | 868540-17-4 |
| Cantidad | 50 mg |
| Objetivo | Proteasome Inhibitors |
| Fórmula molecular | C40H57N5O7 |
| Pureza | 0.98 |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?